EGFR Inhibitors Show Promise Against Immunotherapy-Resistant NF1-Mutant Melanoma

A NYU Langone Health study uncovered a reliance on EGFR signaling in NF1-mutant tumors prompting early-phase trials of cetuximab plus afatinib.